34. Clinical benefit table: Hylan G‐F 20 versus appropriate care. Continuous outcome.

Study	TIme	Treatment	Outcome (scale)	N of Pts	Baseline Mean	End of Study Mean	Absolute Benefit	Relative Difference
Raynauld 2002	45‐52 wk	E: Hylan G‐F 20 + appropriate care	WOMAC pain (0‐20 Likert)	127	11.35	6.94	‐2.57 (I)	‐21.5% (I)
		C: Appropriate care		127	11.94	10.10
Raynauld 2002	45‐52 wk	E: Hylan G‐F 20 + appropriate care	WOMAC function (0‐68 Likert)	127	39.54	24.26	‐8.95 (I)	‐22.3% (I)
		C: Appropriate care		127	40.20	33.87
Raynauld 2002	45‐52 wk	E: Hylan G‐F 20 + appropriate care	SF‐36 Function	127	28.33	33.24	5.31 (I)	18.8% (I)
		C: Appropriate care		126	28.18	27.78
Raynauld 2002	45‐52 wk	E: Hylan G‐F 20 + appropriate care	SF‐36 Mental	127	51.74	55.29	0.81 (I)	1.6% (I)
		C: Appropriate care		126	49.91	52.65
Kahan 2003a	36 wk	E: Hylan G‐F 20 + appropriate care	WOMAC pain (0‐100 mm VAS)	251	50.00	25.40	‐12.4 (I)	‐24.7% (I)
		C: Appropriate care		246	50.30	38.10
Kahan 2003a	36 wk	E: Hylan G‐F 20 + appropriate care	Pain on walking (0‐100 mm VAS)	253	61.10	23.80	‐12.9 (I)	‐21.4% (I)
		C: Appropriate care		253	60.30	35.90
Kahan 2003a	36 wk	E: Hylan G‐F 20 + appropriate care	WOMAC function (0‐100 mm VAS)	251	45.50	27.10	‐11.3 (I)	‐23.8% (I)
		C: Appropriate care		247	47.40	40.30
Kahan 2003a	36 wk	E: Hylan G‐F 20 + appropriate care	WOMAC stiffness (0‐100 mm VAS)	252	45.00	24.40	‐12.9 (I)	‐28.7% (I)
		C: Appropriate care		246	44.90	37.20
Kahan 2003a	36 wk	E: Hylan G‐F 20 + appropriate care	WOMAC total (0‐100 mm VAS)	250	46.30	26.50	‐11.6 (I)	‐24.2% (I)
		C: Appropriate care		245	47.90	39.70
Kahan 2003a	36 wk	E: Hylan G‐F 20 + appropriate care	Lequesne Index (0‐24)	253	11.10	7.50	‐2 (I)	‐17.7% (I)
		C: Appropriate care		253	11.30	9.70